Introduction
Cardiac masses are uncommon findings and can be categorized as either neoplastic or non-neoplastic (Table
1). Neoplastic cardiac masses are comprised of primary benign tumors, primary malignant tumors, or metastatic tumors. Primary cardiac tumors are exceedingly rare with a reported prevalence of 0.001 to 0.03 % in an autopsy series, while metastatic tumors to the heart are reported to be 20 to 40 times more common [
1]. Of all cardiac tumors that originate in the heart (primary), approximately 75 % are benign, with myxoma accounting for at least half of reported cases [
1,
2]. The remaining 25 % of primary cardiac tumors are malignant with sarcoma accounting for a majority of reported cases [
3]. Non-neoplastic cardiac masses, such as thrombi, pericardial cysts, and prominent anatomic structures, can often mimic cardiac tumors. The evaluation of cardiac masses may therefore be a diagnostic challenge.
Table 1
Cardiac neoplasms and commonly-encountered non-neoplastic masses
Benign tumors
| Myxoma |
Lipoma |
Papillary fibroelastoma |
Fibroma |
Hemangioma |
Paraganglioma |
Teratoma |
Atrioventricular (AV) nodal mesothelioma |
Rhabdomyoma |
Malignant tumors
| Metastatic |
Angiosarcoma |
Rhabdomyosarcoma |
Fibrosarcoma |
Lymphosarcoma |
Osteosarcoma |
Liposarcoma |
Mesothelioma |
Non-neoplastic
| Lipomatous hypertrophy of interatrial septum |
Intracardiac thrombus |
Pericardial cyst |
Large coronary artery aneurysm |
Valvular vegetation |
Crista terminalis |
Imaging Approach to Cardiac Masses
Noninvasive imaging plays a critical role in the diagnosis and surgical planning of cardiac masses. Furthermore, certain characteristics identified on imaging may help distinguish neoplastic versus non-neoplastic masses and benign versus malignant tumors (Table
2). Despite the versatility and high accuracy of cardiac computed tomography (cardiac CT) and cardiac magnetic resonance (MR) imaging, echocardiography remains the first-line for cardiac mass evaluation because of its widespread availability, lack of iodinated contrast material or radiation exposure, and its dynamic assessment of cardiac masses in relation to the surrounding chambers, valves, and pericardium. However, echocardiography provides limited assessment of soft-tissue characteristics and extracardiac structures and may be limited by poor acoustic windows, particularly in obese patients and those with chronic lung disease [
4•].
Table 2
Cardiac CT features of benign and malignant tumors
Size/number | Small (<5 cm), single lesion | Large (>5 cm), multiple lesions |
Location | Left > > right | Right > > left |
Morphology | Intracameral | Intramural |
Attachment | Narrow stalk, pedunculated | Broad base |
Enhancement | Absent to minimal | Modest to intense |
Margin | Smooth, well-defined | Irregular, ill-defined |
Invasion | None | Intra-/extracardiac infiltration |
Metastasis | None | May be present |
Pericardial effusion | None | May be present |
Calcification | Rare (except for small foci in fibroma, myxoma, or teratoma) | Large foci in osteosarcoma |
Cardiac CT and MR are often utilized synergistically with echocardiography in the evaluation and management of cardiac masses. Appropriate Use Criteria for cardiac MR [
5] and cardiac CT [
6] and an Expert Consensus statement for pericardial disease imaging [
7••] provide specific guidance on the approach to cardiac masses (Table
3). Cardiac MR is often the preferred imaging modality for cardiac masses because of its superior soft-tissue characterization, high temporal resolution, multiplanar imaging capabilities, and unrestricted field of view [
8]. Since MR does not require the use of ionizing radiation, it is the modality of choice, along with echocardiography, for pediatric patients with cardiac masses. However, cardiac MR is dependent on patient cooperation to obtain quality images and is specifically contraindicated in patients with claustrophobia and implanted magnetic devices. At times, MR may also be limited for evaluating small mobile masses (e.g., papillary fibroelastoma or valvular vegetations) due to limitations in spatial resolution and typically does not provide detailed assessment of the coronary arteries in cases where the assessment of coronary artery disease prior to surgery is an important clinical question.
Table 3
Recommendations for the use of noninvasive imaging to evaluate suspected cardiac and pericardial masses
2006 Appropriate use criteria for cardiac MRI [ 5] - Evaluation of cardiac mass (suspected tumor or thrombus) ……… Appropriate
- Evaluation of pericardial mass ……………………………………. Appropriate
|
2010 Appropriate use criteria for cardiac CT [ 6] - Initial evaluation of cardiac mass (suspected tumor or thrombus) … Inappropriate
- Evaluation of cardiac mass (suspected tumor or thrombus) [when] inadequate images from other noninvasive methods …….… Appropriate
- Evaluation of pericardial anatomy………………………………….. Appropriate
|
2013 Expert consensus for pericardial disease imaging [ 7••] - “Echocardiography is the initial imaging test to assess pericardial masses” - “CT and/or MRI should be done for better tissue characterization of the mass and detection of metastasis (if malignancy is suspected).” |
Cardiac CT is an alternative imaging modality to assess cardiac masses, particularly in patients with known contraindications to MR or in patients with inadequate images from other noninvasive methods. Cardiac CT is a fast imaging technique with electrocardiographic (ECG) gating that provides high quality images with superior spatial resolution. Electrocardiographic gating minimizes motion-related artifacts and allows a more precise delineation of the lesion margins. Compared to other cardiac imaging modalities, CT is optimal for the evaluation of calcified masses, the global assessment of the chest and lung tissue and corresponding vascular structures, and the exclusion of obstructive coronary artery disease or masses which involve the coronary arteries. Significant disadvantages with CT include radiation exposure, a small risk of contrast-induced nephropathy, and lower soft tissue and temporal resolutions as compared with magnetic resonance imaging.
Cardiac CT is also useful to detect metastases in suspected malignancies especially when coupled with
18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET). The ability of
18 F-FDG PET/CT to detect the increased metabolism of glucose may help distinguish malignancy from a benign neoplasm. For example, primary malignant cardiac tumors and metastatic tumors show significantly higher glucose uptake as quantified by
18 F-FDG PET/CT standardized uptake value (SUV) than primary benign cardiac tumors. This differentiation may improve the detection of distant metastases, especially when the results will be used to impact therapy [
9•].
The formulation of a differential diagnosis for cardiac masses on cardiac CT is based on several key aspects. They include size, quantity, location (cardiac chamber, pericardial involvement, extracardiac structures), morphology (attachment, margin appearance, infiltration), tissue characteristics (calcification, fat attenuation, vascularity), and clinical correlation (known malignancy or infection, presence of a catheter, associated syndromes) (Table
4). When performed to assess for cardiac masses, specific CT protocols unique from those typically utilized for coronary imaging can be implemented to obtain high quality images. For example, right atrial or right ventricle masses may require a right heart contrast injection protocol with multiphasic contrast administration to obtain optimal images. Additionally, low dose non-contrast and delayed CT imaging may be helpful in distinguishing intracardiac thrombus from tumor and to detect calcifications. Clinical and imaging features of primary cardiac masses are summarized in Table
2.
Table 4
Cardiac CT features of primary cardiac tumors
Benign (75 %)
|
Myxoma | LA > RA, ventricles | Pedunculated, mobile, heterogeneous, low attenuation, 10 % calcified; may prolapse through the mitral valve |
Lipoma | Varies | Smooth, encapsulated, fat attenuation, no enhancement; multiple lesions may be seen with tuberous sclerosis |
Fibroelastoma | Valves | Small (10 mm), smooth, pedunculated, mobile |
Rhabdomyoma | LV > RV | Smooth, multiple, attenuation similar to myocardium; > 90 % in infants and children |
Fibroma | LV > RV | Homogenous, low attenuation, minimal enhancement, central calcification; second most common in infants and children |
Hemangioma | LV > RV | Heterogeneous, intense enhancement |
Teratoma | Pericardium | Multicystic, moderate enhancement, partially calcified |
Malignant (25 %)
|
Angiosarcoma | RA > RV, pericardium | Broad base, irregular, heterogeneous, low attenuation, infiltrative, pericardial effusion, metastatic |
Rhabdomyosarcoma | Myocardium, valves | Irregular, low attenuation, infiltrative; most common in infants and children |
Fibrosarcoma | LA, pericardium | Large, irregular, low attenuation, central necrosis, infiltrative |
Osteosarcoma | LA > RA, RV | Broad base, low attenuation, infiltrative, extensive calcification |
Liposarcoma | LA > RA, pericardium | Large, fat and soft tissue attenuation, mild contrast enhancement, infiltrative |
Mesothelioma | Pericardium | Infiltrative, variable attenuation, pericardial effusion |
Conclusion
In summary, cardiac CT can provide useful anatomic and functional information as an adjunct to echocardiography and MR in the evaluation of cardiac masses. With high spatial and contrast resolution, fast acquisition times, and the capability to identify calcification and fat, cardiac CT can serve as an ideal alternative to MR imaging, especially in patients with contraindications. Furthermore, cardiac CT may have specific advantages in defining the cardiovascular extent of the mass and excluding coronary artery disease prior to surgical intervention. With the continued, widespread utilization of cardiac CT, it is important to accurately distinguish cardiac masses in order to provide optimal medical management.
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.